Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03174925 · ClinicalTrials.gov registry record · NA
Ultrasound Elastography in Imaging Patients With Thyroid Nodules
A NA study of Thyroid Gland Nodule and Malignant Thyroid Gland Neoplasm, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT03174925: Completed NA study of Thyroid Gland Nodule and Malignant Thyroid Gland Neoplasm, sponsored by Stanford University.
NCT03174925 is a NA study of Thyroid Gland Nodule and Malignant Thyroid Gland Neoplasm that has completed, run by Stanford University. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03174925, a NA study of Thyroid Gland Nodule and Malignant Thyroid Gland Neoplasm, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies how well ultrasound elastography works in assessing the cancer status of potentially malignant thyroid nodules.
Primary Outcome
Potentially cancerous thyroid nodules will be assessed elastographically, and cancer status will be determined from a fine needle aspiration biopsy results or the surgically excised nodule. The outcome will be reported as median tissue stiffness with standard deviation for nodules that were determined non-cancerous (benign), cancerous, or indeterminate.
Conditions Studied
Interventions
- DEVICE Siemens Acuson S3000 ultrasound system
Study Locations (1)
California
- Stanford University, School of Medicine - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2014-01-24 |
| Est. Completion | 2019-02-13 |
| Phase | NA |
What the finished NCT03174925 record still lists
NCT03174925 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Thyroid Gland Nodule appearing as the primary indexed condition, and to 1 intervention - of which Siemens Acuson S3000 ultrasound system is the first listed.
NCT03174925 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03174925 about?
NCT03174925 is a clinical study titled "Ultrasound Elastography in Imaging Patients With Thyroid Nodules". This clinical trial studies how well ultrasound elastography works in assessing the cancer status of potentially malignant thyroid nodules.
What is the current status of trial NCT03174925?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2014-01-24. Estimated completion is 2019-02-13.
What conditions does trial NCT03174925 study?
This clinical trial studies the following conditions: Thyroid Gland Nodule, Malignant Thyroid Gland Neoplasm.
What interventions are being tested in trial NCT03174925?
The interventions under investigation include: Siemens Acuson S3000 ultrasound system (DEVICE).
Who is sponsoring clinical trial NCT03174925?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03174925 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Gland Nodule
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03174925's enrollment target sits among peer trials
55 1264th of 2000 higher than 733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI